Towards optimal management of the axilla in the context of a positive sentinel node biopsy in early breast cancer  

作　　者：Umar Wazir Aisling Manson Kefah Mokbel 

机构地区：[1]The London Breast Institute, Princess Grace Hospital, London W1U 5NY, United Kingdom

出　　处：《World Journal of Clinical Oncology》2014年第5期792-794,共3页世界临床肿瘤学杂志（英文版）

基　　金：Supported by Grants from the Breast Cancer Hope Foundation(London,United Kingdom)

摘　　要：The sentinel lymph node biopsy(SLNB) was initially pioneered for staging melanoma in 1994 and it has been subsequently validated by several trials, and has become the new standard of care for patients with clinically node negative invasive breast cancer. The focussed examination of fewer lymph nodes in addition to improvements in histopathological and molecular analysis has increased the rate at which micrometastases and isolated tumour cells are identified. In this article we review the literature regarding the optimal management of the axilla when the SLNB is positive for metastatic disease based on level 1 evidence derived from randomised clinical trials.The sentinel lymph node biopsy(SLNB) was initially pioneered for staging melanoma in 1994 and it has been subsequently validated by several trials, and has become the new standard of care for patients with clinically node negative invasive breast cancer. The focussed examination of fewer lymph nodes in addition to improvements in histopathological and molecular analysis has increased the rate at which micrometastases and isolated tumour cells are identified. In this article we review the literature regarding the optimal management of the axilla when the SLNB is positive for metastatic disease based on level 1 evidence derived from randomised clinical trials.

关 键 词：SENTINEL LYMPH node biopsy Early breast cancer AXILLARY radiotherapy AXILLARY DISSECTION EVIDENCE-BASED medicine 

分 类 号：R737.9[医药卫生—肿瘤]